ArticlePloS one2024

Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.

Yu-Hao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.